EZZ Life Science Holdings

EZZ

The current EZZ Life Science Holdings (EZZ) market capitalization is approximately A$66.51M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, EZZ Life Science Holdings's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:35 PM Eastern Time

In the most recently reported quarter, EZZ Life Science Holdings (EZZ) generated A$18.29M in revenue, representing a -18.24% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:02 AM Eastern Time

In the most recently reported fiscal year, EZZ Life Science Holdings (EZZ) generated net income of A$6.73M, compared with A$6.96M in the prior fiscal year, representing a -3.36% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of A$9.50M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:02 AM Eastern Time

According to its latest quarterly filing, EZZ Life Science Holdings (EZZ) reported EBITDA of A$2.72M, representing a -34.01% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 2:02 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.01x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 2:02 AM Eastern Time

Based on the latest available data, EZZ Life Science Holdings (EZZ) is currently trading at a last twelve months (LTM) P/E ratio of 9.70x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 2:02 AM Eastern Time

In the most recently reported quarter, EZZ Life Science Holdings (EZZ) revenue was A$18.29M. Earnings per share (EPS) for the quarter were A$0.04. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:02 AM Eastern Time

EZZ Life Science Holdings (EZZ) does not currently pay a dividend. Over the last twelve months (LTM), the company paid A$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 2:02 AM Eastern Time

Analyst assessments of whether EZZ Life Science Holdings (EZZ) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: A$1.41Consensus price target: A$5.00Implied return: +254.61% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 2:02 AM Eastern Time

Based on the latest available analyst coverage, EZZ Life Science Holdings (EZZ) currently carries a NO_OPINION consensus rating. Analysts' average EZZ price target is A$5.00. Relative to the current share price of A$1.41, this suggests a potential price change of approximately +254.61%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 2:02 AM Eastern Time

Like other publicly traded stocks, EZZ Life Science Holdings (EZZ) shares are bought and sold on stock exchanges such as ASX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for EZZ Life Science Holdings (EZZ) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add EZZ to your watchlist.

EZZ Life Science Holdings trades under the ticker symbol EZZ on the ASX stock exchange. The ticker EZZ is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

EZZ Life Science Holdings (EZZ) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest EZZ Life Science Holdings (EZZ) stock peers based on overlapping products, services, and competitive dynamics:BaWang International (Group) Holding (1338) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to EZZ Life Science Holdings.